---
title: "MeiraGTx surges in pre-market trading after reaching a gene therapy collaboration with Eli Lilly"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/265171096.md"
description: "Gene therapy company MeiraGTx Holdings saw its stock price rise 13.22% in pre-market trading on Monday, after the company announced a broad strategic collaboration with Eli Lilly to jointly develop and commercialize gene therapies for eye diseases. Under the agreement, the New York-based biotechnology company will grant Eli Lilly global exclusive rights to its AAV-AIPL1 gene therapy program to develop a treatment for a hereditary eye disease. This disease is Leber Congenital Amaurosis Type 4 (LCA4), caused by a defect in the aryl hydrocarbon interacting protein-like 1 (AIPL1) gene, which MeiraGTx has identified as one of the most severe hereditary retinal dystrophies. According to the agreement, the Indiana-based pharmaceutical giant will also gain rights to several other gene therapy technologies from MeiraGTx. In exchange, MeiraGTx will receive a $75 million upfront payment and will be eligible for over $400 million upon achieving certain milestones. Additionally, the company will qualify for tiered royalties from potential sales of the licensed products"
datetime: "2025-11-10T13:54:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265171096.md)
  - [en](https://longbridge.com/en/news/265171096.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265171096.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/265171096.md) | [繁體中文](https://longbridge.com/zh-HK/news/265171096.md)


# MeiraGTx surges in pre-market trading after reaching a gene therapy collaboration with Eli Lilly

According to Zhitong Finance APP, gene therapy company MeiraGTx Holdings (MGTX.US) saw its stock price rise 13.22% in pre-market trading on Monday, after the company announced a broad strategic collaboration with Eli Lilly (LLY.US) to jointly develop and commercialize gene therapies for eye diseases.

Under the agreement, the New York-based biotechnology company will grant Eli Lilly global exclusive rights to its AAV-AIPL1 gene therapy program to develop a treatment for a hereditary eye disease.

This disease is Leber Congenital Amaurosis Type 4 (LCA4), caused by a defect in the Arylhydrocarbon Interacting Protein Like 1 (AIPL1) gene, which MeiraGTx has identified as one of the most severe hereditary retinal disorders.

According to the agreement, the Indiana-based pharmaceutical giant will also gain rights to several other gene therapy technologies from MeiraGTx.

In exchange, MeiraGTx will receive a $75 million upfront payment and will receive over $400 million upon achieving certain milestones. Additionally, the company will be eligible to receive tiered royalties from potential sales of the licensed products

### Related Stocks

- [MeiraGTx Holdings plc (MGTX.US)](https://longbridge.com/en/quote/MGTX.US.md)
- [Eli Lilly and Company (LLY.US)](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

- [MeiraGTx Highlights Late-Stage Gene Therapy Pipeline at RBC Ophthalmology Conference](https://longbridge.com/en/news/280608481.md)
- [MeiraGTx Extends Perceptive Notes to May 2027, Plans $25M Redemption; Warrants Repriced to $8](https://longbridge.com/en/news/280630952.md)
- [Ocugen Updates Roadmap for Gene-Agnostic Retinal Therapies](https://longbridge.com/en/news/280790760.md)
- [Lexeo Therapeutics Advances Cardiac Gene Therapies, Strengthens Finances](https://longbridge.com/en/news/281090118.md)
- [Neurogene Advances Rett Gene Therapy Toward BLA With Strong Cash Runway](https://longbridge.com/en/news/280377541.md)